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Abstract
Background: Mutations in COL8A2 gene which encodes the collagen alpha-2 (VIII) chain have been identified in
both familial and sporadic cases of Fuchs endothelial corneal dystrophy (FECD). Heterozygous mutations in the
SLC4A11 gene are also known to cause late-onset FECD. Therefore we screened for COL8A2, SLC4A11 gene variants
in Indian FECD patients.
Methods: Eighty patients with clinically diagnosed FECD and 100 age matched normal individuals were recruited.
Genomic DNA was isolated from peripheral blood leukocytes. Mutations in COL8A2, SLC4A11 coding regions were
screened using bi-directional sequencing. Fischer’s exact test or Pearson’s chi squared test were used to predict the
statistical association of genotypes with the phenotype.
Results: Screening of COL8A2 gene revealed 2 novel c.1610G>A, c.1643A>G and 3 reported variations c.112G>A,
c.464G>A and c.1485G>A. In SLC4A11 gene, novel c.1659C>T, c.1974C>T and reported c.405G>A, c.481A>C and
c.639G>A variants were identified. However all the variations in both the genes were also present in unaffected
controls.
Conclusions: This is the first study analysing COL8A2 gene in Indian patients with FECD. No pathogenic mutations
were identified in COL8A2. Merely silent changes, which showed statistically insignificant association with FECD,
were identified in the screening of SLC4A11 gene. These results suggest that COL8A2, SLC4A11 genes may not be
responsible for FECD in patients examined in this study.
Background
The corneal endothelial dystrophies comprising Fuchs
endothelial corneal dystrophy (FECD; MIM#s 136800
and 610158), posterior polymorphous corneal dystrophy
(PPCD; MIM#s 122000, 609140 and 609141) and conge-
nital hereditary endothelial dystrophy (CHED;
MIM121700 and 217700) are thought to represent
defects of neural crest terminal differentiation [1]. FECD
is a degenerative, bilateral, often asymmetric and slowly
progressive disorder [2]. It is characterized by a pleo-
morphic, attenuated, dysfunctional and degenerated cor-
neal endothelium and the progressive formation of
microscopic, refractile, posterior excrescences in the
Descemet membrane (a collagen rich basal lamina)
secreted by corneal endothelium, clinically known as
corneal guttae [3]. Due to endothelial dysfunction and
loss of cells with FECD progression leads to corneal
decompensation and impaired vision [4].
FECD may show familial clustering but it is usually a
sporadic condition [5,6]. It occurs predominantly in
females compared to the males [2,7]. Corneal grafting is
the only means of restoring vision in advanced cases,
however there is always the risk for allograft rejection
and requires lifelong follow up.
The genotypic approach will provide better under-
standing, identification of the underlying genetic defects
and in future enhance the possibility of medical inter-
vention using conventional pharmacological approaches
or gene therapy. Family based studies have mapped late-
onset FECD susceptibility loci to 13ptel-13q12.13 [8]
and 18q21.2-q21.32 [9]. Genome wide linkage analysis
of 22 families with FECD identified potential linkage
regions on chromosomes 1, 7, 15, 17, and X [10].
Recently FECD is linked to a novel locus on
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5q33.1-q35.2 [11]. Mutations in the COL8A2 gene
located on 1p34.3 have been described in patients with
FECD [12-16]. This gene encodes for the collagen
alpha- 2 (VIII) chain, a major component of Descemet
membrane. This protein is found in the posterior
banded layer (PBL) of patients with FECD [17,18].
Heterozygous mutations in the SLC4A11 gene are also
known to be associated with the late-onset FECD [19].
The SLC4A11 gene, which codes for sodium bicarbonate
transporter-like protein 11 have been previously asso-
ciated with autosomal recessive congenital hereditary
endothelial dystrophy (CHED2) that also arises by the
primary defect in the corneal endothelium [20].
Susceptibility of genes to mutations can vary in differ-
ent ethnicities and also in view of the limited informa-
tion on the genetics of FECD from India, we undertook
this study. We screened for mutation in the COL8A2
and SLC4A11 genes to determine whether these genes
are responsible for causing FECD in Indian population.
We report for the first time, the results of mutation ana-
lysis of the COL8A2 gene in 80 unrelated patients with
early onset & late onset FECD. A study by Vithana et
al., screened 25 Indian FECD patients for SLC4A11
mutations [19], this is the first report of analysing




All the patients and normal controls screened were
recruited from Aravind Eye Hospital (A tertiary eye care
centre), Madurai, Tamilnadu, India. Eighty patients stu-
died were sporadic cases of Indian ancestry. One hun-
dred control individuals without any eye disease were
enlisted. The study protocol had the approval of Institu-
tional Review Board of Aravind Eye Hospital. Informed
consent was obtained from each individual and all stu-
dies were performed according to the tenets of the
Declaration of Helsinki. All patients underwent a com-
plete ophthalmic evaluation including a detailed medical
and family history. The presence of guttae was identified
using the slit lamp and confirmed by specular micro-
scopy. Histopathological examination of corneas col-
lected from the patients who underwent penetrating
keratoplasty (PKP) was also done.
Mutation analysis
DNA was isolated from peripheral blood lymphocytes
using the protocol described by Miller et al., (1988) [21].
Polymerase chain reaction (PCR) was used to amplify
the 2 exons of COL8A2 (NM_005202) using 16 sets of
oligonucleotide primer pairs and PCR conditions were
followed as previously described in the literature [12].
For mutational analysis of SLC4A11 (NM_032034) gene,
all the coding exons of SLC4A11 and their flanking
splice junctions were amplified by means of PCR using
the primers reported elsewhere [20]. The PCR products
were purified using a gel extraction kit (Amersham Bios-
ciences, Piscataway, NJ), and bi-directional sequencing
was performed using an ABI 3130 sequencer (Applied
Biosystems, Foster City, CA).
Statistical analysis
Data was analysed using Stata 8 (Stata, college station,
TX). Statistical differences in allele and genotype fre-
quencies between the case and the control groups were
determined using Pearson’s chi-squared test or by
Fischer’s exact test respectively.
Prediction of splice site alteration
To identify whether the variants found are causing any
splice site alteration, a program for recognizing the
splice sites was used http://www.fruitfly.org/seq_tools/
splice.html.
Results
Eighty unrelated patients with a diagnosis of either early
or late-onset FECD were enrolled in the study. All of
them were sporadic cases and no family history of dis-
ease was observed. Among the 80 patients, 27 were men
and 53 were women. Age of onset of symptoms was
between 17 to 76 years. The probands’ onset of symp-
toms within 40 years of age was considered as early
onset and above 40 years as late onset. Fifteen cases
came under the early onset category in which 5 were
males and 10 were females. Their age ranged from 26 to
40 years with an average of 33.6 years (Standard Devia-
tion (SD) 5.1). The age of 65 late onset cases ranged
from 42 to 76 years with an average range of 55 years
(SD 8.3) including 20 males and 45 females. The 100
unrelated controls age range was 25 to 70 years with an
average of 50 years (SD 12.42). Among the 80 FECD
patients 37 patients underwent PKP (bilateral- 11, uni-
lateral- 26), the age at surgery was between 36 to 77
years and all the cases were confirmed to have FECD by
histopathological examination. Epithelial, stromal edema
and thickened Descemet membrane was seen in all the
buttons including the presence of guttae in longstanding
cases.
Screening of the COL8A2 gene in the affected patients
did not reveal any of the previously identified patho-
genic mutations associated with FECD [12,13,15], and
[16]. The reported c.464G>A (p.Arg155Gln) [12,16] var-
iant, novel variants c.1610G>A (p.Asp537Asn) and
c.1643A>G (p.Asn548Ser) (Figure 1a, b) were found
both in controls and patients with statistically insignifi-
cant association with the disease. Reported silent var-
iants c.112G>A (p. =), c.1485G>A (p. =) [12] were also
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identified. The p values of these alleles showed signifi-
cant association with the disease however the odds ratio
(OR) was significantly lesser on comparing the disease
with controls (Table 1).
SLC4A11 gene screening did not identify any patho-
genic mutation. However 2 novel variants c.1659C>T (p.
=), c.1974C>T (p. =) (Figure 1c, d) and 3 reported var-
iants c.405G>A (p. =), c.481A>C (p. =), c.639G>A (p. =)
[19] were identified. None of the variants were found to
have any statistically significant association with the dis-
ease (Table 1). Moreover variants identified in COL8A2
and SLC4A11 did not seem to alter any splice site.
Discussion
The exact cause of FECD is still unknown. To under-
stand the pathogenesis, we screened for COL8A2 and
SLC4A11 gene variants in our study. Previous studies in
other ethnic groups identified pathogenic mutations in
COL8A2 in association with FECD [12-16]. Biswas et al.,
[12] reported that p.Gln455Lys was detected in 3 early
onset FECD families originating from Northern England
and Australia. Also in their study, missense mutations p.
Arg155Gln, p.Arg304Gln and p.Arg434His were identi-
fied in the common, late onset form of FECD. Similar
to this report the heterozygous p.Gln455Lys mutation
was also identified in Korean patients with FECD [16].
Gottsch et al., [13] reported the segregation of COL8A2
p.Leu450Trp with the disease phenotype in American
familial FECD with early onset subtype. A study by Lis-
kova et al., also observed the same mutation in a British
family with early-onset FECD [15].
At birth, the normal endothelial cells start producing the
posterior non-banded layer and continue to add material
throughout life. In FECD and CHED2, Descemet mem-
brane may appear thickened as the posterior layer is atte-
nuated or absent and is replaced by an abnormal banded
layer (varying from 14 to 20 μm, unlike the normal thick-
ness 12 μm) due to endothelial dysfunction. This common
clinical feature implies that SLC4A11 gene, the causative
gene for CHED2 may play a role in FECD, even though
the onset and symptoms of CHED2 and FECD are com-
pletely dissimilar. This is supported by the identification of
heterozygous missense mutations in the SLC4A11 gene in
Chinese and Indian FECD patients [19].
Figure 1 Sequence chromatograms of the FECD patients showing the variants along with the controls. a, b. Novel variants identified in
the COL8A2 gene. c, d. Novel variants identified in SLC4A11 gene. The underline marks the mutated codon. The arrow indicates heterozygous
state of the sequence.
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Table 1 Allele and genotype frequencies of COL8A2 and SLC4A11 variants
Gene Variation FECD Normal P-value
(n = 80) % (n = 100) %
COL8A2 c.112G>A (p. =) Genotype GG 67 83.8 93 93 0.104
GA 9 11.3 6 6
AA 4 5 1 1
Allele G 143 0.894 192 0.96 0.014
A 17 0.106 8 0.04 0.014
c.464G>A (Arg155Gln) Genotype GG 79 98.8 93 93 NS
GA 0 0.0 5 5
AA 1 1.25 2 2
Allele G 158 0.987 191 0.955 NS
A 2 0.012 9 0.045
c.1485G>A (p. =) Genotype GG 62 77.5 91 91 0.028
GA 13 16.3 8 8
AA 5 6.3 1 1
Allele G 137 0.856 190 0.95 0.002
A 23 0.144 10 0.05 0.002
c.1610G>A (Asp537Asn)* Genotype GG 78 97.5 95 95 NS
GA 2 2.5 5 5
AA 0 0.0 0 0.0
Allele G 158 0.987 195 0.975 NS
A 2 0.012 5 0.025
c.1643A>G (Asn548Ser)* Genotype AA 75 93.8 93 93 NS
AG 5 6.3 7 7
GG 0 0.0 0 0.0
Allele A 155 0.969 193 0.965 NS
G 5 0.131 7 0.035
SLC4A11 c.405G>A (p. =) Genotype GG 78 97.5 94 94 NS
GA 2 25 6 6
AA 0 0.0 0 0.0
Allele G 158 0.98 194 0.97 NS
A 2 0.012 6 0.015
c.481A>C (p. =) Genotype AA 76 95 93 93 NS
AC 4 5 7 7
CC 0 0.0 0 0.0
Allele A 156 0.975 193 0.96 NS
C 4 0.025 7 0.035
c.639G>A (p. =) Genotype GG 79 98.75 95 95 NS
GA 1 1.25 5 5
AA 0 0.0 0 0.0
Allele G 159 0.99 195 0.97 NS
A 1 0.006 5 0.025
c.1659C>T (p. =) * Genotype CC 72 90 95 95 NS
CT 8 10 5 5
TT 0 0.0 0 0.0
Allele C 152 0.95 195 0.97 NS
T 8 0.05 5 0.025
c.1974C>T (p. =) * Genotype CC 76 95 91 91 NS
CT 4 5 9 9
TT 0 0.0 0 0
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In the present study we did not identify any patho-
genic mutations in COL8A2 in association with FECD.
Even though association of c.112G>A (p. =) and
c.1485G>A (p. =) was identified with FECD patients,
these mutations may not be considered as pathogenic
because they do not produce any change in the encoded
amino acid and also do not alter the splice site. Similarly
a study by Afshari et al., [10] did not identify p.
Leu450Trp and p.Gln455Lys variants in their study of
screening 92 FECD patients. Kobayashi et al., [22] and
Mok et al., [16] observed p.Arg155Gln and p.Thr502Met
variations in the COL8A2 gene but there were no statis-
tically significant differences in the frequencies of these
2 variations between the affected individuals and control
subjects. In other 4 independent studies no mutations
were identified in COL8A2 in association with both
early and late-onset FECD [23-26].
In SLC4A11 screening, we identified 2 novel and 3
reported silent variants which had no significant associa-
tion with FECD and did not identify any pathogenic var-
iants. By the screening of 25 Indian FECD cases Vithana
et al., identified a presumed pathogenic variant
c.1195G>A (p.Glu399Lys) in SLC4A11 in a single spora-
dic case. Though they found association of SLC4A11
with FECD, the mutations contribute to only 5% of the
genetic burden of the disease [19].
Conclusions
This is the first report analysing the COL8A2 gene in
association with Indian FECD patients and we addition-
ally studied the SLC4A11 gene in large number of
Indian cohort. In the patients screened, we did not iden-
tify any pathogenic variants in both the genes making it
unlikely that single nucleotide polymorphisms or muta-
tions in them cause FECD. The possibility of pathogenic
changes being within the promoter, intronic or untrans-
lated non coding regions of these genes playing a role in
the pathogenesis of FECD has not been excluded in this
study.
Together with information from previous investiga-
tions, our study suggests that locus heterogeneity exist
for FECD, wherein mutations of several genes on differ-
ent chromosomes may produce a common disease phe-
notype. In addition to the genomic approach,
proteonomic approach may also shed light on the dis-
ease pathogenesis.
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